CN109239373A - A kind of tissue factor carboxylate reagent and the preparation method and application thereof - Google Patents
A kind of tissue factor carboxylate reagent and the preparation method and application thereof Download PDFInfo
- Publication number
- CN109239373A CN109239373A CN201810927731.9A CN201810927731A CN109239373A CN 109239373 A CN109239373 A CN 109239373A CN 201810927731 A CN201810927731 A CN 201810927731A CN 109239373 A CN109239373 A CN 109239373A
- Authority
- CN
- China
- Prior art keywords
- tissue factor
- carboxylate
- reagent
- concentration
- buffer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The present invention relates to a kind of tissue factor carboxylate reagents and the preparation method and application thereof, belong to technical field of in vitro diagnostic reagents.It solves and how the technical issues of a kind of at low cost, stability is good, tissue factor carboxylate reagent with long preservation period and the preparation method and application thereof is provided.Reagent of the invention, including recombination rabbit tissue factor, synthetic phospholipid, stabilizer and buffer；Wherein, concentration of the recombination rabbit tissue factor in reagent is 1 μ g/ml；Synthetic phospholipid is made of phosphatidylserine, phosphatidyl choline, phosphatidyl glycerol and cholesterol, and concentration of the synthetic phospholipid in reagent is 250 μ g/ml；Stabilizer is made of glycerol, glucose and ferulic acid.Type, proportion of the tissue factor carboxylate reagent by adjusting synthetic phospholipid, stabilizer and buffer, have that at low cost, stability is high, advantage with long preservation period.
Description
Technical field
The invention belongs to external diagnosis reagent material technology fields, and in particular to a kind of tissue factor carboxylate reagent and
Preparation method and application.
Background technique
Tissue factor is a kind of protein.At present both at home and abroad used genetic engineering means Escherichia coli, fungi or
Expression product tissue factor in zooblast.The Chinese patent of Publication No. 101294163B is using genetic engineering means in yeast
Middle successful expression human recombination factor.This method than it is traditional from animal tissue extract tissue factor it is highly efficient and produce
Product purity is higher.Tissue factor mixes with a certain proportion of phosphatide and is capable of forming tissue factor carboxylate.It is organized in carboxylate
The factor is embedded into the surface of liposome of phospholipid bilayer formation.Tissue factor carboxylate can effectively activate exogenous blood coagulation way
Diameter and the preparation for being frequently utilized for prothrombin time (PT) detection kit.Traditionally tissue factor carboxylate is often from animal tissue
Middle extraction, if the PT reagent of Shanghai Sun Company, Inc. extracts tissue factor carboxylate from rabbit brain tissue, and Siemens Company be from
It is extracted in Human plactnta.Phosphatide is contained in this tissue factor naturally extracted, therefore has not needed additionally to add phosphatide.It
The tissue factor carboxylate so extracted is influenced vulnerable to many factors, such as the age of animal or people, gender, diet, individual difference
Deng to the content of tissue factor and phosphatide ingredient and content be affected.Different phosphatide composition and content, different tissues because
Sub- content is obvious to the detection effect difference of PT reagent.This be also the main reason for causing PT detection kit differences between batches big it
One.Using genetic engineering means preparation tissue factor and the tissue factor carboxylate that is mixed with out of a certain proportion of phosphatide by
In definite ingredients, technique can controllably effectively reduce the difference between batch of PT detection kit.Domestic tissue factor esterification at present
There are Taiyuan Bo Aote, Qingdao Condar etc. in object manufacturer.However commercial product is on the high side, limits its popularization and use.
Summary of the invention
The present invention in view of the shortcomings of the prior art, provide a kind of tissue factor carboxylate reagent and the preparation method and application thereof,
The tissue factor carboxylate reagent is provided with that at low cost, stability is good, advantage with long preservation period.
It is as follows that the present invention solves the technical solution that above-mentioned technical problem is taken.
The present invention provides a kind of tissue factor carboxylate reagent, including recombinates rabbit tissue factor, synthetic phospholipid and contain steady
Determine the buffer of agent；
Concentration of the recombination rabbit tissue factor in reagent is 1 μ g/ml；
The synthetic phospholipid is made of phosphatidylserine, phosphatidyl choline, phosphatidyl glycerol and cholesterol, phosphatidyl silk
Propylhomoserin, phosphatidyl choline, phosphatidyl glycerol and cholesterol mass ratio be 3:6:0:1,3:3:3:1,3:0:3:4 or 0:3:3:4,
In reagent, concentration of the synthetic phospholipid in reagent is 250 μ g/ml；
The stabilizer is made of glycerol, glucose and ferulic acid, and glycerol, glucose and ferulic acid are dense in buffer
Degree is followed successively by 10%, 5%, 0.02%, is perhaps 12%, 5%, 0.02% or is 7%, 3%, 0.02%, Huo Zhewei
10%, 5%, 0.01%, or be 12%, 5%, 0.01%.
Preferably, 0.02%-0.1% preservative is also contained in reagent.
It is further preferred that the concentration of the preservative is 0.05%.
Preferably, the preservative is Sodium azide and/or Proclin 300.
Preferably, the buffer is PBS buffer solution, Tris buffer or HEPES buffer solution.
It is further preferred that the concentration of the buffer is 20mM.
The present invention also provides the preparation methods of above-mentioned tissue factor carboxylate reagent, and steps are as follows:
Step 1: phosphatidylserine, phosphatidyl choline, phosphatidyl glycerol and cholesterol are mixed according to the ratio, closed
At phosphatide；
Step 2: synthetic phospholipid and surfactant are mixed, it is completely dissolved synthetic phospholipid after mixing, it is mixed to obtain first
Solution is closed, the concentration of synthetic phospholipid is 35mg/ml in the first mixed solution；
Step 3: recombination rabbit tissue factor is added into the first mixed solution, after mixing, it is stirred at room temperature and is incubated for 4h, obtain
The concentration for recombinating rabbit tissue factor is the second mixed solution of 80-120 μ g/ml, and it is molten that the second mixing is removed by the way of dialysis
Surfactant in liquid obtains recombination rabbit tissue factor carboxylate；
Step 4: the recombination rabbit tissue factor carboxylate obtained with the buffer dilution step three containing stabilizer, obtains
Tissue factor carboxylate reagent.
Preferably, in step 2, the surfactant is cocoyl glycine potassium, cocoyl glucoside, cocounut oil
Amido propyl betaine or n-octyl glucopyranoside glycosides.
Preferably, in step 3, the mode of the dialysis are as follows: the second mixed solution is transferred in bag filter, every
4h dialysis is primary, dialyses five times altogether, removes surfactant.
The present invention also provides above-mentioned tissue factor carboxylate reagents to prepare answering in prothrombin time detection kit
With.
Compared with prior art, the invention has the benefit that
1, tissue factor carboxylate reagent of the invention by adjusting synthetic phospholipid, stabilizer and buffer type, match
Than, have that at low cost, stability is high, advantage with long preservation period, specific:
Tissue factor carboxylate reagent of the invention, component is clear, overcome the tissue that naturally extracts in the prior art because
Sub- carboxylate type and content are unknown, the big technical problem of differences between batches；
Tissue factor carboxylate reagent of the invention uses phosphatidylserine, phosphatidyl choline, phosphatidyl glycerol and gallbladder
Sterol can effectively improve tissue factor carboxylate using glycerol, glucose and ferulic acid as stabilizer as synthetic phospholipid
Stability.
2, tissue factor carboxylate reagent of the invention can be directly used for the use of PT detection reagent, be esterified for tissue factor
The popularization and application of object provide foundation.
Specific embodiment
For a further understanding of the present invention, the preferred embodiment of the invention is described below, but it is to be understood that this
A little descriptions are only further explanation the features and advantages of the present invention, rather than limiting to the claimed invention.
The present invention provides a kind of tissue factor carboxylate reagent, including recombination rabbit tissue factor, synthetic phospholipid, stabilizer and
Buffer；Wherein,
Recombinating concentration of the rabbit tissue factor in reagent is 1 μ g/ml；
Synthetic phospholipid is made of phosphatidylserine, phosphatidyl choline, phosphatidyl glycerol and cholesterol, phosphatidyl silk ammonia
Acid, phosphatidyl choline, phosphatidyl glycerol and cholesterol mass ratio be 3:6:0:1,3:3:3:1,3:0:3:4 or 0:3:3:4, it is excellent
Synthetic phospholipid is selected to be made of phosphatidylserine, phosphatidyl choline and the cholesterol that mass ratio is 3:6:1, synthetic phospholipid is in reagent
In concentration be 250 μ g/ml；
Stabilizer is made of glycerol, glucose and ferulic acid, the concentration of glycerol, glucose and ferulic acid in buffer according to
Secondary is 10%, 5%, 0.02%, be perhaps 12%, 5%, 0.02% be perhaps 7%, 3%, 0.02% or be 10%,
5%, 0.01%, or be 12%, 5%, 0.01%.
In above-mentioned technical proposal, for the stability for further enhancing reagent, tissue factor carboxylate reagent can also include
Preservative, the concentration of preservative are 0.02%-0.1%, preferably 0.05%；Preservative is preferably Sodium azide and/or Proclin
300。
In above-mentioned technical proposal, buffer is buffer commonly used in the art, such as PBS buffer solution, Tris buffer or HEPES
Buffer, concentration are preferably 20mM.
The present invention also provides the preparation methods of above-mentioned tissue factor carboxylate reagent, and steps are as follows:
Step 1: by phosphatidylserine, phosphatidyl choline, phosphatidyl glycerol and cholesterol be in mass ratio 3:6:3:1,
3:3:3:1,3:0:3:4 or 0:3:3:4 mixing, obtain synthetic phospholipid；
Step 2: synthetic phospholipid and surfactant are mixed, it is completely dissolved synthetic phospholipid after mixing, it is mixed to obtain first
Solution is closed, the concentration of synthetic phospholipid is 35mg/ml in the first mixed solution；
Wherein, surfactant is preferably cocoyl glycine potassium, cocoyl glucoside, Cocoamidopropyl betaine
Or n-octyl glucopyranoside glycosides, especially preferably cocoyl glucoside；
Step 3: recombination rabbit tissue factor is added into the first mixed solution, after mixing, it is stirred at room temperature and is incubated for 4h, obtain
The concentration for recombinating rabbit tissue factor is the second mixed solution of 80-120 μ g/ml, and it is molten that the second mixing is removed by the way of dialysis
Surfactant in liquid obtains recombination rabbit tissue factor carboxylate；
Wherein, the mode of dialysis are as follows: the second mixed solution is transferred in bag filter, it is primary every 4h dialysis, it dialyses altogether
Five times, remove surfactant；
Step 4: the recombination rabbit tissue factor carboxylate of synthesis is diluted with the buffer containing stabilizer, until containing 1 μ g/ml
Recombination rabbit tissue factor and 250 μ g/ml synthetic phospholipids, as tissue factor carboxylate reagent；
Wherein, stabilizer is made of glycerol, glucose and ferulic acid, and glycerol, glucose and ferulic acid are in buffer
Concentration is followed successively by 10%, 5%, 0.02%, is perhaps 12%, 5%, 0.02% or is 7%, 3%, 0.02%, Huo Zhewei
10%, 5%, 0.01%, or be 12%, 5%, 0.01%；
When tissue factor carboxylate reagent contains preservative, according to the proportion by preservative, with containing stabilization in step 4
The buffer of agent adds together.
The present invention also provides above-mentioned tissue factor carboxylate reagents to prepare answering in prothrombin time detection kit
With.
The present invention is further illustrated with reference to embodiments.
Embodiment 1
The preparation of tissue factor carboxylate reagent, steps are as follows；
Step 1: pressing the proportion of table 1, the phosphatidylserine, phosphatidyl choline, phosphatidyl glycerol of each formula are weighed respectively
And cholesterol obtains synthetic phospholipid after mixing；
Step 2: synthetic phospholipid is mixed with surfactant, it is completely dissolved synthetic phospholipid after mixing, obtains mixing molten
Liquid, wherein the final concentration of 35mg/ml of synthetic phospholipid；
Step 3: pressing the proportion of table 1, recombination rabbit tissue factor is added into the mixed solution of each formula respectively, recombinates rabbit
The final concentration of 120 μ g/ml of tissue factor after mixing, is stirred at room temperature and is incubated for 4h, and obtained solution is transferred in bag filter, often
It is primary every 4h dialysis, it dialyses five times altogether, removes surfactant, obtain recombination rabbit tissue factor carboxylate；
Step 4: with containing 10% glycerol, 5% glucose and 0.02% ferulic acid Tris buffer dilution step
Three obtained recombination rabbit tissue factor carboxylates obtain recombination rabbit tissue factor and the 250 μ g/ml synthetic phospholipids containing 1 μ g/ml
Tissue factor carboxylate reagent.
The composition and proportion for the formula that the tissue factor carboxylate reagent of 1 embodiment 1 of table uses
In table 1, percentage sign indicates substance shared mass percent in synthetic phospholipid.
Using the clotting time of the tissue factor carboxylate reagent measurement normal plasma of embodiment 1, acquired results are shown in Table 2 institutes
Show.
The clotting time of the tissue factor carboxylate reagent measurement normal plasma of 2 embodiment 1 of table
As seen from Table 2, by the result of the tissue factor carboxylate reagent measurement of the square 1-4 preparation in table 1 in normal model
It encloses, wherein side 1 illustrates phosphatidylserine, phosphorus that synthetic phospholipid is preferably 3:6:1 by mass ratio close to reference interval median
Phosphatidylcholine and cholesterol composition.
Embodiment 2
Surfactant in side 1 in embodiment 1 is changed to cocoyl glycine potassium, cocoyl glucoside respectively
And Cocoamidopropyl betaine, synthetic tissue factor carboxylate reagent (composition and proportion of specific formula are shown in Table 3) is prepared,
He is same as Example 1.
The composition and proportion for the formula that the tissue factor carboxylate reagent of 3 embodiment 2 of table uses
In table 2, percentage sign indicates substance shared mass percent in synthetic phospholipid.
Using the clotting time of the tissue factor carboxylate reagent measurement normal plasma of embodiment 2, acquired results are shown in Table 4 institutes
Show.
The clotting time of the tissue factor carboxylate reagent measurement normal plasma of 4 embodiment 2 of table
As seen from Table 4, the result of the tissue factor carboxylate reagent measurement prepared by side 1, side 5, side 6 and the side 7 in table 3
In normal range (NR), wherein side 1 is close to reference interval median.Illustrate that reagent of the present invention preferably uses cocoyl glucoside as table
Face activating agent.
Embodiment 3
The preparation of tissue factor carboxylate reagent, steps are as follows:
Step 1: phosphatidylserine, phosphatidyl choline and cholesterol 3:6:1 in mass ratio are mixed, obtained synthesis
Phosphatide；
Step 2: synthetic phospholipid and cocoyl glucoside solution are mixed, after being completely dissolved synthetic phospholipid after mixing, obtain
To mixed solution, the final concentration of 35mg/ml of synthetic phospholipid；
Step 3: recombination rabbit tissue factor is added into mixed solution, the final concentration of 120 μ g/ of rabbit tissue factor is recombinated
Ml after mixing, is stirred at room temperature and is incubated for 4h, cocoyl glucoside is removed by the way of dialysis, and recombination rabbit tissue factor ester is obtained
Compound；
Step 4: according to the proportion of table 5, the recombination that is respectively obtained step 3 with the Tris buffer containing different stabilizers
Rabbit tissue factor carboxylate dilution, to containing 1 μ g/ml recombination rabbit tissue factor and 250 μ g/ml synthetic phospholipids, as tissue because
Sub- carboxylate reagent.
In 5 embodiment 3 of table in the different Tris buffers containing stabilizer stabilizer composition
In table 5, percentage sign indicates substance shared mass percent in Tris buffer.
Using the clotting time of the tissue factor carboxylate reagent measurement normal plasma of embodiment 3, acquired results are shown in Table 6 institutes
Show.
The clotting time of the tissue factor carboxylate reagent measurement normal plasma of 6 embodiment 3 of table
As seen from Table 6, the group of tissue factor carboxylate preparation is prepared by side 1, side 9, side 11, side 15 and the side 16 in table 5
Factor carboxylate reagent measurement result is knitted in normal range (NR).
Embodiment 4
According to the proportion of table 7, the tissue factor that embodiment 1 is added in the preservative of variety classes different amounts is esterified respectively
In object reagent.
The preservative of the tissue factor carboxylate reagent of 7 embodiment 4 of table forms and proportion
In table 7, percentage sign indicates preservative shared mass percent in tissue factor carboxylate reagent.
By the reagent of embodiment 4 after 37 DEG C are placed 7 days, the clotting time of quality-control product is measured, acquired results are shown in Table 8 institutes
Show.
The clotting time of the tissue factor carboxylate reagent measurement quality-control product of 8 embodiment 4 of table
As can be seen from Table 8, the tissue factor carboxylate reagent measurement result of square 17-22 preparation is in term of reference.
The foregoing description of the disclosed embodiments enables those skilled in the art to implement or use the present invention.
Various modifications to these embodiments will be readily apparent to those skilled in the art, as defined herein
General Principle can be realized in other embodiments without departing from the spirit or scope of the present invention.Therefore, of the invention
It is not intended to be limited to the embodiments shown herein, and is to fit to and the principles and novel features disclosed herein phase one
The widest scope of cause.
Claims (10)
1. tissue factor carboxylate reagent, which is characterized in that including recombination rabbit tissue factor, synthetic phospholipid, stabilizer and buffering
Liquid；
Concentration of the recombination rabbit tissue factor in reagent is 1 μ g/ml；
The synthetic phospholipid is made of phosphatidylserine, phosphatidyl choline, phosphatidyl glycerol and cholesterol, phosphatidyl silk ammonia
Acid, phosphatidyl choline, phosphatidyl glycerol and cholesterol mass ratio be 3:6:0:1,3:3:3:1,3:0:3:4 or 0:3:3:4, close
It is 250 μ g/ml at concentration of the phosphatide in reagent；
The stabilizer is made of glycerol, glucose and ferulic acid, the concentration of glycerol, glucose and ferulic acid in buffer according to
Secondary is 10%, 5%, 0.02%, be perhaps 12%, 5%, 0.02% be perhaps 7%, 3%, 0.02% or be 10%,
5%, 0.01%, or be 12%, 5%, 0.01%.
2. tissue factor carboxylate reagent according to claim 1, which is characterized in that also contain 0.02%- in reagent
0.1% preservative.
3. tissue factor carboxylate reagent according to claim 2, which is characterized in that the concentration of the preservative is
0.05%.
4. tissue factor carboxylate reagent according to claim 2, which is characterized in that the preservative be Sodium azide and/
Or Proclin 300.
5. tissue factor carboxylate reagent according to claim 1, which is characterized in that the buffer be PBS buffer solution,
Tris buffer or HEPES buffer solution.
6. tissue factor carboxylate reagent according to claim 1, which is characterized in that the concentration of the buffer is
20mM。
7. the preparation method of tissue factor carboxylate reagent described in claim 1-6 any one, which is characterized in that step is such as
Under:
Step 1: phosphatidylserine, phosphatidyl choline, phosphatidyl glycerol and cholesterol are mixed according to the ratio, synthesis phosphorus is obtained
Rouge；
Step 2: synthetic phospholipid and surfactant are mixed, it is completely dissolved synthetic phospholipid after mixing, it is molten to obtain the first mixing
Liquid, the concentration of synthetic phospholipid is 35mg/ml in the first mixed solution；
Step 3: recombination rabbit tissue factor is added into the first mixed solution, after mixing, it is stirred at room temperature and is incubated for 4h, recombinated
The concentration of rabbit tissue factor is the second mixed solution of 80-120 μ g/ml, is removed in the second mixed solution by the way of dialysis
Surfactant, obtain recombination rabbit tissue factor carboxylate；
Step 4: the recombination rabbit tissue factor carboxylate obtained with the buffer dilution step three containing stabilizer, obtains tissue
Factor carboxylate reagent.
8. the preparation method of tissue factor carboxylate reagent according to claim 7, which is characterized in that in step 2, institute
Stating surfactant is cocoyl glycine potassium, cocoyl glucoside, Cocoamidopropyl betaine or n-octyl pyrans Portugal
Polyglycoside.
9. the preparation method of tissue factor carboxylate reagent according to claim 7, which is characterized in that in step 3, institute
State the mode of dialysis are as follows: the second mixed solution is transferred in bag filter, it is primary every 4h dialysis, it dialyses five times altogether, removes table
Face activating agent.
10. tissue factor carboxylate reagent described in claim 1-6 any one is preparing prothrombin time detection reagent
Application in box.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810927731.9A CN109239373A (en) | 2018-08-15 | 2018-08-15 | A kind of tissue factor carboxylate reagent and the preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810927731.9A CN109239373A (en) | 2018-08-15 | 2018-08-15 | A kind of tissue factor carboxylate reagent and the preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109239373A true CN109239373A (en) | 2019-01-18 |
Family
ID=65069609
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810927731.9A Pending CN109239373A (en) | 2018-08-15 | 2018-08-15 | A kind of tissue factor carboxylate reagent and the preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109239373A (en) |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5314695A (en) * | 1990-11-13 | 1994-05-24 | Corvas International, Inc. | Tissue factor based prothrombin time reagent |
| US6183979B1 (en) * | 1999-03-24 | 2001-02-06 | International Technidyne Corporation | Preparation of dried synthetic prothrombin time reagents |
| CN101666806A (en) * | 2008-09-07 | 2010-03-10 | 上海长岛生物技术有限公司 | Preparation method for liquid thrombin time (TT) detection reagent |
| CN103472235A (en) * | 2013-08-26 | 2013-12-25 | 河北省科学院生物研究所 | Long-acting protein solution stabilizing agent |
| CN104914256A (en) * | 2014-03-13 | 2015-09-16 | 基立福有限公司 | Composition for use as an abnormal coagulation control plasma in in vitro assays |
| CN106337044A (en) * | 2016-09-30 | 2017-01-18 | 四川迈克生物科技股份有限公司 | Thrombin solution |
| CN107356768A (en) * | 2017-06-23 | 2017-11-17 | 宁波艾科生物科技有限公司 | A kind of liquid instant prothrombin time detection reagent |
-
2018
- 2018-08-15 CN CN201810927731.9A patent/CN109239373A/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5314695A (en) * | 1990-11-13 | 1994-05-24 | Corvas International, Inc. | Tissue factor based prothrombin time reagent |
| US6183979B1 (en) * | 1999-03-24 | 2001-02-06 | International Technidyne Corporation | Preparation of dried synthetic prothrombin time reagents |
| CN101666806A (en) * | 2008-09-07 | 2010-03-10 | 上海长岛生物技术有限公司 | Preparation method for liquid thrombin time (TT) detection reagent |
| CN103472235A (en) * | 2013-08-26 | 2013-12-25 | 河北省科学院生物研究所 | Long-acting protein solution stabilizing agent |
| CN104914256A (en) * | 2014-03-13 | 2015-09-16 | 基立福有限公司 | Composition for use as an abnormal coagulation control plasma in in vitro assays |
| CN106337044A (en) * | 2016-09-30 | 2017-01-18 | 四川迈克生物科技股份有限公司 | Thrombin solution |
| CN107356768A (en) * | 2017-06-23 | 2017-11-17 | 宁波艾科生物科技有限公司 | A kind of liquid instant prothrombin time detection reagent |
Non-Patent Citations (2)
| Title |
|---|
| 刘林杰: "当归活性组分阿魏酸的电化学分析研究", 《中国优秀硕士学位论文全文数据库 工程科技I辑》 * |
| 蒋文雯等: "抑制组织因子活性的天然化合物研究近况 ", 《药学进展》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Heerklotz et al. | Leakage and lysis of lipid membranes induced by the lipopeptide surfactin | |
| DE60012785T2 (en) | RECONSTRUCTION OF CLEANED MEMBRANE PROTEINS IN PRE-PRODUCED LIPOSOMES | |
| US5043164A (en) | Blood-stable, cholesterol-free liposomes | |
| DE69131204T3 (en) | PROTHROMBIN TIME REAGENT BASED ON TISSUE FACTOR | |
| Nakajima et al. | Interaction between liposomes and sarcotoxin IA, a potent antibacterial protein of Sarcophaga peregrina (flesh fly). | |
| Gabriel et al. | Spontaneous formation of stable unilamellar vesicles | |
| Papahadjopoulos et al. | Interaction of a purified hydrophobic protein from myelin with phospholipid membranes: Studies on ultrastructure, phase transitions and permeability | |
| Mason et al. | The antibiotic and DNA‐transfecting peptide LAH4 selectively associates with, and disorders, anionic lipids in mixed membranes | |
| Bearer et al. | Fusion of phospholipid vesicles arrested by quick-freezing. The question of lipidic particles as intermediates in membrane fusion | |
| US20130149374A1 (en) | Asymmetric Liposomes for the Highly Efficient Encapsulation of Nucleic Acids and Hydrophilic Anionic Compounds, and Method for Preparing Same | |
| Machado et al. | Osmotic response in Lactobacillus casei ATCC 393: biochemical and biophysical characteristics of membrane | |
| JPH06201702A (en) | Liquid thromboplastein reagent | |
| TW201206446A (en) | Lipoprotein formulation and production method thereof | |
| EA024074B1 (en) | Aqueous adjuvant composition comprising a non-ionic isotonicity agent, immunogenic composition and kit based thereon and process for preparing an immunogenic composition | |
| KR101840037B1 (en) | Vesicle composition, and external skin preparation and cosmetic, each contaning same | |
| Howell et al. | Macromolecular assemblies of lipid in bile | |
| Rath et al. | Cord factor (trehalose 6, 6′-dimycolate) forms fully stable and non-permeable lipid bilayers required for a functional outer membrane | |
| Jurado et al. | Physical studies on membrane lipids of Bacillus stearothermophilus temperature and calcium effects | |
| Berliner et al. | Manganese (II) electron spin resonance and cadmium-113 nuclear magnetic resonance evidence for the nature of the calcium binding site in. alpha.-lactalbumins | |
| CN109239373A (en) | A kind of tissue factor carboxylate reagent and the preparation method and application thereof | |
| US20050175681A1 (en) | Liposomal vitamin a and method of preparation | |
| Yeagle | Incorporation of the human erythrocyte sialoglycoprotein into recombined membranes containing cholesterol | |
| Pinnaduwage et al. | β-Galactosidase-induced destabilization of liposome composed of phosphatidylethanolamine and ganglioside GM1 | |
| CN104837479B (en) | Vesicle composition and the skin preparations for extenal use and cosmetics compounded with the vesicle composition | |
| Morrow et al. | Studies on the interaction of human erythrocyte band 3 with membrane lipids using deuterium nuclear magnetic resonance and differential scanning calorimetry |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20190118 |